Could the 1990s surge of biotech investment be happening again?
With new legislation, mergers and IPOs all helping lead the way, the biotech industry is seeing levels of investment not seen in recent years.
Earlier this year, the industry gained notice with several big-name mergers and acquisitions, such as GlaxoSmithkline's acquisition of Human Genome Sciences for $3 billion in August, and Spectrum Pharmaceuticals Inc.'s $206 million purchase of Allos Therapeutics in April. There also has been a surge of new FDA approvals that have attracted investor attention--including a drug from Onyx Pharmaceuticals to treat a rare blood cancer and an obesity drug from VIVUS Inc.
To read the original article: New Regulations Could be a Boon to Bio-Tech - Sponsored - The Atlantic
